List of Excipients in Branded Drug MIEBO

« Back to Dashboard

MIEBO Excipient Strategy and Commercial Opportunities in Dry-Eye Pharmaceuticals

Last updated: September 25, 2026

MIEBO is a differentiated ophthalmic product because its formulation contains perfluorohexyloctane as the active ingredient and does not depend on conventional aqueous excipients such as buffers, surfactants, polymers, or preservatives. The formulation strategy reduces preservative toxicity and aqueous-phase instability, but shifts value toward fluorinated-liquid manufacturing, container-closure performance, dose delivery, and intellectual-property control.

The principal commercial opportunities are preservative-free ocular products, combination products using MIEBO as a lipid-layer platform, optimized multidose delivery systems, and manufacturing technologies that improve fill accuracy and patient handling. MIEBO is not a biologic and has no biosimilar pathway. Generic competition would likely proceed through an abbreviated new drug application, subject to formulation, device, equivalence, and patent barriers.

What is MIEBO and how does its formulation work?

MIEBO is the U.S. brand name for perfluorohexyloctane ophthalmic solution, marketed by Bausch + Lomb. The U.S. Food and Drug Administration approved MIEBO in May 2023 for the treatment of signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.[1]

Perfluorohexyloctane is a semifluorinated alkane. Unlike conventional artificial tears, it is not an aqueous solution that primarily supplements the water phase of the tear film. Its proposed role is to reduce excessive evaporation from the ocular surface by spreading across the tear-film lipid layer.[1]

Product characteristic	MIEBO profile
Active ingredient	Perfluorohexyloctane
Dosage form	Ophthalmic solution
Route	Topical ocular administration
Preservative status	Preservative-free
Conventional aqueous vehicle	None disclosed in the FDA label
Dosing	One drop in each affected eye four times daily
FDA pathway	New drug application
First U.S. approval	May 2023
Therapeutic area	Dry eye disease associated with Meibomian gland dysfunction
Manufacturer	Bausch + Lomb
Original technology company	Novaliq

The lack of a conventional aqueous vehicle is central to the product’s commercial positioning. MIEBO avoids the compatibility problems associated with water-soluble drugs, ionic buffers, antimicrobial preservatives, and polymeric viscosity agents.

What excipients are used in MIEBO?

The FDA prescribing information identifies perfluorohexyloctane as the active ingredient and does not list conventional inactive ingredients for the marketed ophthalmic solution.[1] In practical terms, MIEBO is a single-component drug formulation rather than a conventional drug-plus-excipient system.

This formulation creates several implications:

1. There is no buffer system to optimize ocular pH.
2. There is no aqueous solvent requiring microbial preservation.
3. There is no surfactant or emulsifier needed to disperse the active ingredient.
4. There is no viscosity polymer controlling residence time.
5. There is no conventional lipid excipient serving as the primary evaporation barrier.

The formulation’s simplicity does not eliminate pharmaceutical-development complexity. It transfers that complexity to physical-property control and packaging.

Which formulation attributes matter most?

The critical quality attributes are likely to include:

• Perfluorohexyloctane identity and chemical purity.
• Fluorinated impurity profile.
• Water content.
• Nonvolatile residue.
• Optical clarity and absence of particulates.
• Density and viscosity.
• Drop size and delivered volume.
• Extractables and leachables from the container.
• Closure integrity.
• Stability under temperature and light exposure.

A fluorinated liquid can interact differently with elastomers, plastics, coatings, and adhesives than aqueous ophthalmic products. Container-closure selection therefore has greater commercial and regulatory significance than an ordinary inactive-ingredient optimization program.

How does MIEBO’s excipient strategy compare with conventional dry-eye products?

MIEBO differs from the major classes of dry-eye products because it uses a nonaqueous active liquid rather than an aqueous tear substitute.

Product category	Typical formulation	Preservative risk	Primary commercial differentiation
Conventional artificial tears	Water, salts, polymers, surfactants	Present in some multidose products	Lubrication and viscosity
Lipid-containing tears	Aqueous emulsion with oils or phospholipids	Depends on product	Evaporation reduction and lipid replenishment
Cyclosporine ophthalmic products	Aqueous or emulsion system with solubilizers	Product-specific	Anti-inflammatory activity
Lifitegrast	Aqueous ophthalmic solution	Preservative-free product	Anti-inflammatory activity
MIEBO	Perfluorohexyloctane without conventional excipients	Preservative-free	Direct evaporation barrier

The absence of excipients can be a competitive advantage in patients who experience irritation from preserved products or who need frequent administration. It also provides a clearer product story for ophthalmologists treating evaporative dry eye and Meibomian gland dysfunction.

What commercial opportunities exist around MIEBO excipients?

The largest opportunity is not adding excipients to MIEBO. It is developing enabling technologies around the drug substance and delivery system.

Preservative-free ocular delivery

MIEBO supports a growing market for preservative-free therapies. Patients with chronic dry eye may administer topical products several times daily, increasing cumulative exposure to preservatives such as benzalkonium chloride. Products that avoid preservatives can compete in chronic-use segments and in patients with ocular-surface disease.

Commercial opportunities include:

• Preservative-free multidose bottles.
• Unit-dose presentations.
• Low-waste metered-dose systems.
• Device systems with antimicrobial protection that do not rely on preservatives.
• Patient-friendly packaging for elderly users and patients with limited dexterity.

Container-closure systems

The container is a high-value component of the MIEBO platform. A successful package must maintain chemical compatibility, prevent evaporation, control drop size, and avoid contamination during repeated use.

Potential technology suppliers include manufacturers of:

• Fluoropolymer-coated primary containers.
• Low-sorption polymer bottles.
• Precision ophthalmic droppers.
• Metered-dose pumps.
• One-way valves.
• Sterile barrier systems.
• Extractables and leachables testing services.

The commercial advantage of a specialized package is that it can create switching costs even when the active ingredient is chemically simple.

Alternative delivery formats

MIEBO is currently delivered as an ophthalmic drop. Alternative formats could expand use cases, although each would require new regulatory and clinical work.

Potential formats include:

• Single-use ampoules for severe dry-eye patients.
• Metered-dose multidose containers.
• Applicators designed to reduce missed drops.
• Combination packs pairing MIEBO with anti-inflammatory treatment.
• Post-procedure ocular-surface products.
• Products designed for contact-lens-related evaporative symptoms, subject to compatibility testing.

A spray or gel format would be technically more complex because perfluorohexyloctane’s spreading behavior, dose delivery, and ocular residence time could change materially with the device and administration method.

What manufacturing and IP barriers protect MIEBO?

MIEBO’s commercial barrier is likely to be a combination of composition-of-matter claims, therapeutic-use claims, formulation claims, manufacturing controls, and container-closure know-how.

Manufacturing barriers

Commercial-scale manufacture must control:

• Raw-material purity.
• Fluorinated impurities.
• Water exclusion.
• Sterile filling.
• Drop-volume consistency.
• Vapor loss during processing.
• Compatibility with filling equipment.
• Batch-to-batch physical-property variation.

Sterile manufacture of a nonaqueous fluorinated liquid may require specialized process validation. Conventional aqueous ophthalmic manufacturing equipment may not transfer directly without changes in materials, seals, filling parameters, and cleaning validation.

Patent categories

The relevant patent categories are likely to include:

Patent category	Commercial relevance
Perfluorohexyloctane composition patents	Protect the active compound or defined chemical compositions
Ophthalmic-use patents	Cover treatment of dry eye, evaporative dry eye, or Meibomian gland dysfunction
Formulation patents	Cover concentration, purity, water limits, or specific liquid systems
Delivery patents	Protect bottles, droppers, pumps, or dose-control systems
Manufacturing patents	Cover purification, filling, sterilization, or handling methods
Combination patents	Protect use with anti-inflammatory or other ocular therapies

The precise enforceability of each claim depends on claim scope, patent term, prosecution history, and any terminal disclaimers. The FDA Orange Book and USPTO records are the controlling sources for current listed patents and expiration data.[2][3]

What is the FDA and Orange Book status of MIEBO?

MIEBO was approved under NDA 216675 in 2023.[1] It is a small-molecule ophthalmic drug, not a biologic. The relevant abbreviated pathway for a future generic would generally be an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The FDA approval establishes the regulatory reference product. A generic applicant would need to address:

• Pharmaceutical equivalence.
• Same active ingredient and dosage form.
• Equivalent strength.
• Equivalent route of administration.
• Bioequivalence or other FDA-accepted equivalence evidence.
• Sterility and microbial quality.
• Container-closure performance.
• Drop-size and delivered-dose characteristics.
• Listed patents and regulatory exclusivities.

MIEBO’s nonaqueous formulation may make conventional in vitro equivalence more important. The applicant could face questions about physicochemical equivalence, ocular distribution, drop behavior, evaporation, and device performance.

Does MIEBO have biosimilar risk?

No. MIEBO is not a biologic and cannot be challenged through the biosimilar pathway. Competitive products would enter through generic-drug procedures, a new NDA, or potentially another regulatory pathway depending on formulation and claim scope.

When does MIEBO lose exclusivity?

MIEBO’s market exclusivity has two separate components: FDA regulatory exclusivity and patent exclusivity.

The FDA granted MIEBO new chemical entity exclusivity associated with its 2023 approval. NCE exclusivity generally blocks submission of an ANDA or 505(b)(2) application referencing the product for five years, subject to statutory exceptions for Paragraph IV patent challenges.[4]

The practical generic-entry date depends on:

• The end of NCE exclusivity.
• The expiration of listed patents.
• Any pediatric exclusivity.
• Litigation timing.
• Court-ordered stays.
• The scope of approved method-of-use claims.
• Whether a challenger can use a section viii statement to omit patented indications.

A definitive launch forecast requires reviewing the current Orange Book patent listing, FDA exclusivity data, and any Paragraph IV litigation docket. Patent expiration dates should not be inferred solely from the product’s approval date.

What Paragraph IV challenges and litigation risks exist?

A future ANDA applicant could file a Paragraph IV certification asserting that an MIEBO patent is invalid, unenforceable, or not infringed. If the patent holder sues within the statutory period, FDA approval of the ANDA can be subject to a 30-month stay, subject to court and regulatory developments.[4]

The strongest potential challenge targets would likely be:

• Narrow method-of-use claims.
• Formulation claims that depend on limited concentration or impurity ranges.
• Later-issued delivery-device patents.
• Manufacturing claims with design-around options.
• Claims vulnerable to written-description or obviousness attacks.

The strongest defenses would likely center on the unusual ocular use of perfluorohexyloctane, the formulation’s physical properties, and claim language linking the compound to evaporative dry-eye treatment.

No biosimilar litigation framework applies. Generic litigation would likely focus on the Orange Book-listed patents and the ANDA applicant’s certification strategy.

Which companies are positioned to challenge or compete with MIEBO?

MIEBO competes across several layers rather than against one identical product.

Competitive group	Examples	Threat type
Prescription dry-eye drugs	Cyclosporine products, lifitegrast	Different mechanism and physician substitution
Lipid-containing artificial tears	Multiple OTC brands	Lower price and retail availability
Evaporation-reduction products	Lipid-layer and oil-based drops	Clinical and commercial substitution
Generic manufacturers	Large ANDA filers	Long-term price erosion
Device companies	Ophthalmic pump and metered-dose suppliers	Delivery-system differentiation
Combination-product developers	Drug developers with anti-inflammatory agents	Broader disease management

Bausch + Lomb’s commercial position benefits from an established ophthalmic sales infrastructure and broad access to eye-care professionals. The main constraint is pricing pressure from over-the-counter products and the need to demonstrate durable clinical differentiation in a crowded dry-eye market.

How much revenue exposure does MIEBO create?

MIEBO creates direct revenue exposure to the prescription dry-eye market and indirect exposure to related products, including ocular lubricants, lid-margin therapies, and Meibomian gland dysfunction diagnostics.

The key commercial variables are:

• Prescription conversion from artificial tears.
• Refill persistence.
• Insurance coverage and patient copay.
• Adoption by optometrists and ophthalmologists.
• Use in evaporative rather than aqueous-deficient disease.
• Competitive response from lipid-based products.
• Timing of generic entry.
• Ability to maintain a premium price for a preservative-free product.

A simple formulation can support premium pricing when the clinical message is clear: chronic dry-eye patients receive a preservative-free product designed to reduce evaporation. The commercial risk is that payers or physicians may view MIEBO as substitutable with lower-cost lipid-containing lubricants.

How strong is the MIEBO patent estate?

MIEBO’s patent strength is likely strongest where claims connect the active ingredient to a specific ocular indication, formulation behavior, or delivery system. Composition claims are valuable but depend heavily on remaining patent term and claim breadth.

The estate is commercially stronger when it combines:

• A core active-ingredient patent.
• A dry-eye or Meibomian gland dysfunction use patent.
• A formulation patent.
• A package or delivery patent.
• Manufacturing know-how that is difficult to replicate.

The estate is weaker if protection depends mainly on narrow method-of-use claims, if the formulation is readily replicated, or if the package can be redesigned without affecting therapeutic equivalence.

Key Takeaways

• MIEBO is a preservative-free, nonaqueous ophthalmic solution containing perfluorohexyloctane.
• Its formulation does not rely on conventional aqueous excipients, buffers, surfactants, polymers, or preservatives.
• The principal excipient-related opportunity is in container-closure systems, dose-control devices, unit-dose packaging, and manufacturing technologies.
• MIEBO is regulated as a small-molecule drug, not a biologic, so biosimilar risk does not apply.
• Future generic competition would likely proceed through an ANDA and could involve Paragraph IV challenges.
• The commercial moat depends on patents, FDA exclusivity, package performance, manufacturing know-how, clinical differentiation, and physician adoption.
• MIEBO competes with prescription anti-inflammatory therapies, lipid-containing artificial tears, and lower-cost OTC products.
• Its strongest formulation advantage is the combination of preservative-free use and a direct evaporation-barrier mechanism.

FAQs About MIEBO Formulation and Commercial Strategy

Is MIEBO an emulsion?

No. MIEBO is labeled as a perfluorohexyloctane ophthalmic solution. It is not a conventional aqueous oil-in-water emulsion.[1]

Does MIEBO contain benzalkonium chloride?

The FDA label does not identify benzalkonium chloride as an inactive ingredient. MIEBO is marketed as preservative-free.[1]

Can a generic manufacturer add excipients to MIEBO?

Adding excipients could create a different formulation and may prevent the product from meeting pharmaceutical-equivalence requirements. A generic applicant would need FDA acceptance of its formulation and equivalence approach.

Is perfluorohexyloctane used in other FDA-approved eye drops?

MIEBO is the FDA-approved ophthalmic product specifically identified with perfluorohexyloctane as its active ingredient. The compound’s commercial use in ophthalmology is closely associated with Novaliq’s and Bausch + Lomb’s product platform.

What is the largest commercial opportunity around MIEBO?

The largest adjacent opportunity is a preservative-free delivery platform that improves multidose dosing, limits evaporation and contamination, and maintains consistent drop size for a chemically simple fluorinated liquid.

References

1. U.S. Food and Drug Administration. (2023). MIEBO (perfluorohexyloctane ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. United States Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System.
4. U.S. Food and Drug Administration. (2024). Approved drug products and regulatory exclusivity provisions under the Federal Food, Drug, and Cosmetic Act.